Nevertheless, given the evidence that combined anti-IL-6/ICI treatment enhances the antitumoral effect, an important question is whether a rechallenge after mild CRS/HLH that responded well to anti-IL-6 treatment or corticosteroids should be considered. The gene discussed is IL6; the disease is congenital rubella syndrome.